$SVRS forming a multi year cup and handle breakoutTSXV:SVRS is a compelling setup, nearly 8 years of consolidation (cup phase) followed by an impulse movement in 2020, and again 5 year long time correction handle pattern. This is a solid setup which we don't find often. What i like is the volume buildup near the handle phase, which is a clear institutional smart money surge.
I am buying here, and clearly this is not a short term trade. My downside risk is capped at 30%.
CSE:QIMC-Drilling for clean energy & AI-Massive upside potential
💡 Fundamental Catalyst: The Next-Gen Energy Play (Natural Hydrogen & AI)
QIMC is positioning itself as a vertically integrated player in the future of clean energy and data infrastructure—a powerful, dual-engine narrative:
* Natural Hydrogen Pioneer : The company is aggressively exploring and confirming deep natural hydrogen systems in Nova Scotia and other regions. This is a massive, green energy source with significant recent milestones:
* New Discoveries : Confirmation of multiple m
Price action The upcoming earnings report for Loblaw Companies Limited on November 13, 2024, could significantly impact its stock price. Currently, the stock is trading in a tight and shrinking range, suggesting a period of consolidation. This limited movement reflects caution in the market, with investors awaiting confirmation of a breakout or breakdown. If the earnings report meets or exceeds expectations, this may trigger upward momentum, breaking the current range and setting a bullish trend. However, a
Leveraging HMM.A's Demand Zone and Descending Triangle PatternWhen HMM.A (TSX) reaches the demand zone between $7.91 and $8.10 and coincides with the closing of the currently forming descending triangle at the drawn demand line, I plan to initiate a buy position. This decision aligns with my strategy to capitalize on potential increased demand and the pattern's breakout. My exit goal for this trade is set between $8.36 and $8.62.
Hemostemix Inc. is on a mission to flourish the health sector .(TSX: HEM) There are several top stem cell companies that are engaged in various activities related to stem cell research, development, and commercialization. The top companies are engaged in the development of regenerative medicine products based on mesenchymal lineage adult stem cells. The top stem cell companies are engaged in various activities related to stem cell research, development, and commercialization, with the ultimate goal of developing new treatments and therapies for a range of d
$HEM ,major smallcap biotech play with picture perfect financialThe global biotechnology market was estimated to be worth USD 859.94 billion in 2022 and is expected to be worth around USD 1,683.52 billion by 2030, with a notable CAGR of 8.7% from 2023 to 2030. Investors should pay attention to productive small caps in the game, such as $HEM, which has shown immense growth potential in the years to come. Hemostemix, Inc. has announced good clinical trial findings for the treatment of CLI and angina, indicating that its treatments have the potential to address
Hemostemix continues to flourish in the healthcare sector.Hemostemix Inc. (TSXV: HEM) has emerged as a pioneer biotechnology company in the healthcare sector. This company is continuously thriving to shape and develop blood-derived stem cell therapies for medical conditions. With its innovative approach and proficient technology, the company constantly tries to improve the lives of patients with cardiovascular diseases, autoimmune diseases, and other medical conditions. Hemostemix Inc. tries to revolutionize the field of regenerative medicine by offeri
$HEM has the power to be the next big thing in healthcare stocksHemostemix (HEM) is a biotechnology company that develops and commercializes innovative stem cell therapies for medical conditions that are currently underserved by existing treatments. HEM's proprietary technology allows it to isolate and culture a patient's own stem cells, which are then used to treat a variety of conditions, including critical limb ischemia, diabetic foot ulcers, and multiple sclerosis. HEM has been making waves in the healthcare sector, and investors are starting to take not
Hemostemix Inc. continues to flourish in the healthcare sector.Hemostemix Inc. (TSXV: HEM) has emerged as a pioneer biotechnology company in the healthcare sector. This company is continuously thriving to shape and develop blood-derived stem cell therapies for medical conditions. With its innovative approach and proficient technology, the company constantly tries to improve the lives of patients with cardiovascular diseases, autoimmune diseases, and other medical conditions. Hemostemix Inc. tries to revolutionize the field of regenerative medicine by offeri
$DIA success is a short race $DIA is responsible for seventy percent of all millionaires. This stock has made more money than all other industrial investments combined. Today's wise young person or wage earner invests their money in $DIA.
DLong
Universal Ibogaine’s stock approved by borse Frankfurt
UI's common shares have been listed for trading on the Frankfurt Stock Exchange, or Bourse Frankfurt, under the ticker symbol "JC4". In Canada, UI will continue to trade on the TSX Venture Exchange under the ticker IBO and on the OTCQB under the ticker symbol IBOGF.
$IBO destined to be on top of the TSX-V index
$IBO is one of the handpicked penny stocks in the market today and is racing ahead with full speed, the stock’s financial figures are pretty neat and is expected achieve great heights in the days to come, shares are trading yesterday at $0.0500 with a distinctive spike
Perks handed to UI upon listing on the Frankfurt stock exchangeThe Frankfurt Stock Exchange (FSE) is Germany's largest stock exchange and the leading European destination for Canadian venture capital firms seeking exposure and liquidity in the European market. The FSE enables advanced electronic trading, settlement, and information technologies, allowing it to handle the increasing demands of cross-border trading.






















